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Abstract
Background:  Hyperandrogenic conditions have been associated with a high prevalence of
endometrial pathologies related to cell survival. However, the action of androgens on proliferation
and apoptosis in endometrial cells is poorly understood. Therefore, the aim of the present study
was to evaluate the effect of androstenedione on cell proliferation, cell death and expression of
estrogen receptor (ER) isoforms and proteins related to apoptosis in endometrial cells using two
in vitro experimental approaches.
Methods: The endometrial tissue was obtained from 20 eumenorrheic women [28.7 (25 – 35)
years] during the early secretory phase. We analyzed cell proliferation (immunohistochemistry of
Ki-67 and spectrophotometric assay); apoptosis (DNA fragmentation (TUNEL) and Annexin V-
FITC binding); ER-alpha, ER-beta bcl-2 and bax mRNA abundance (RT-PCR) in explants and
isolated endometrial epithelial (EEC) and stromal cells (ESC) incubated with androstenedione 1
micro mol/l (A4) or A4 plus hydroxyflutamide 10 micro mol/l (F) for 24 h.
Results: In explants, A4 induced an increase of cell proliferation and a decrease on apoptosis in
the stromal compartment (p < 0.05). In isolated ESC, proliferation augmented with A4 (p < 0.05),
whereas, no significant modifications in the expression of ER-alpha, ER-beta bcl-2 and bax nor in
the apoptotic index were observed. In EEC, A4 increase the ER-beta mRNA abundance (p < 0.05)
and a decrease of the bcl-2/bax ratio (p < 0.05), without an increase in the apoptotic index.
Hydroxyflutamide reverted the effect of androstenedione on the parameters described.
Conclusions: These results indicate that androstenedione may modulate cell survival, expression
of ER-beta and proteins related to apoptosis, suggesting a potential mechanism that associates the
effect of hyperandrogenemia on the endometrial tissue.
Background
Polycystic ovary syndrome (PCOS) is a complex endo-
crine-metabolic disorder, associated to hyperandrogen-
ism, menstrual disturbances and in many cases to insulin
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resistance [1,2]. It has been observed that in some of
PCOS women, the endometrium is thicker than that of
normal cycling women [3] and a higher prevalence of
endometrial hyperplasia and adenocarcinoma have also
been described in these women [4-6]. The latter may indi-
cate that the mechanisms that regulate the process of cell
survival may be disrupted in the endometrium of PCOS
women. Recently, we have shown that the expression of
proteins involved in the regulation of apoptosis in PCOS
endometria were altered [7]. Besides, we and other inves-
tigators demonstrated an elevated expression of the estro-
gen receptor (ER) and its co-activators in endometria of
women bearing this syndrome [7-9]. Nevertheless, in
those studies it was difficult to establish the exact contri-
bution of androgens as a regulatory steroid of endometria
of PCOS women, since multiple factors could be affecting
their endometrial function, including hyperinsulinemia
and the possible contribution of the unopposed effect of
estrogens [10,11]. Therefore, in vitro experimental models
such as tissue and cell culture may constitute interesting
approaches to determine the potential role of androgens
in the regulation of endometrial cell survival.
Early reports in isolated endometrial stromal cells (ESC)
have shown that androgens can induce decidualization
and inhibition of the expression of ER and progesterone
receptors [12,13]. Moreover, in endometrial epithelial
cells (EEC), androgens altered the expression of proteins
related to uterine receptivity [8] and induced a decrease in
the proliferation capacity of those cells [14].
Cell proliferation and apoptosis of the endometrium are
importantly regulated by the expression of ER [15], which
exists in two major subtypes, estrogen receptors alpha
(ERα) and estrogen receptor beta (ERβ). The two isoforms
of ER derive from separate genes, with different ligand
binding affinities and the response of the tissue to estro-
gens will depend upon their relative concentrations [16].
On the other hand, in some tissues including the human
endometrium, the control of apoptosis has been associ-
ated to proteins related to the Bcl-2 family, like Bcl-2 that
promotes cell survival and Bax which is an inducer of
apoptosis [17,18]. Evenmore, other proteins are involved
in the machinery of cell death like caspases which are
associated with the cleavage and thus, breakdown of cell
structure [19]. In regard to this issue, we have demon-
strated that the expression of bcl-2 and bax is increased in
the stromal compartment of the endometrium of PCOS
women, but we could not observe an increase in the apop-
totic index in the endometria of these women [7].
Previous reports have shown that androstenedione is an
important androgen detected in the endometrial tissue
[20,21]. Therefore, based on the amount of androgens
normally found in endometria and their potential impor-
tance in alterations of the endometrial cell survival in
PCOS women, the objective of the present study was to
evaluate the effect of androstenedione on cell prolifera-
tion, apoptosis and the expression of ER isoforms and
proteins related to apoptosis using two in vitro experi-
mental approaches.
Methods
Subjects
Endometrial tissue was obtained with pipelle suction
curette from the corpus of the uteri of 20 women with reg-
ular menstrual cycles, aged 28.7 (25 – 35) years, at the
time of bilateral tubal ligation at the San Borja-Arriarán
Clinical Hospital, National Health Service, Santiago,
Chile. The tissue was obtained during the early secretory
phase since the cells obtained from this phase maintain a
high degree of proliferation capacity [22]. None of these
women had taken oral contraceptives or other medica-
tions for at least 6 months before starting the study.
Women who had evidences of PCOS, endometriosis and/
or endometrial hyperplasia were excluded. This investiga-
tion was approved by the Institutional Ethics Committee
of the San Borja-Arriarán Clinical Hospital and an
informed written consent was obtained from all subjects.
Culture System
Explants
Human endometrium was cut into slices (20 to 50 mg wet
weight) and incubated in 1 mL of Hank's media supple-
mented with 2 mmol/L glutamax-I (BRL, Life Technology,
Bethesda, MD, USA), insulin-transferrin-selenium (ITS)
solution (BRL), 0.1% w/v bovine serum albumin (BSA;
Sigma Chemical Co., St Louis, MO, USA), 26 mmol/L of
NaHCO3, 25 mmol/L of HEPES aminoacids solution, 100
IU/ml of penicillin, and 5 mg/mL of streptomycin
(Sigma). Incubation was performed during 6 h at 37°C in
5% CO2/air in humidified atmosphere in the absence or
presence of androstenedione 10-7 to 10-5 M (Sigma) or
androstenedione 10-6 M plus hydroxyflutamide 10-5 M
(Sigma), the latter added 30 min before androstenedione.
After incubation, one piece from both basal and treated
tissue explants were frozen in liquid N2 and maintained at
-70°C for RT-PCR protocols. Another piece was fixed in
4% buffered formaldehyde for 24 h, embedded in paraf-
fin, and cut into 5 µm thick sections before in situ analysis
of apoptosis and immunohistochemistry.
Cells
The cells were separated and purified according to previ-
ously described methods [23]. Briefly, the tissue was cut
into small pieces and suspended in Dulbecco's modified
Eagle medium (DMEM) (GibcoBRL), collagenase (370
IU/100 mg tissue) (Worthington, Biochemical Corp. Free-
hold, NJ, USA) and DNAse (14 KU/100 mg tissue)Reproductive Biology and Endocrinology 2004, 2:81 http://www.rbej.com/content/2/1/81
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(Sigma) during 1 h at 37°C. Epithelial cells, predomi-
nantly from glands, were separated from ESC by decanta-
tion and the supernatant containing the ESC was filtered,
centrifuged and the cell pellet washed in DMEM. Stromal
cells were incubated in appropriate cell culture media
(ESC media) (DMEM/MCDB-105 (3:1 v/v), 2% charcoal
stripped fetal bovine serum (FBS) (GibcoBRL), insulin-
transferrin-selenium (ITS) solution, 2 mmol/L glutamax-I
(GibcoBRL), 0.25 µg/mL ascorbic acid (GibcoBRL), 0.25
µg/mL fungizone (GibcoBRL), 100 IU/mL penicillin and
5 mg/mL streptomycin at 37°C in 5% CO2/air in humid-
ified atmosphere until confluence.
The glands cells were washed in DMEM and incubated for
1 h (30 min in each side of the culture flask), and then cul-
tured in EEC culture media (DMEM/MCDB-105 (3:1, v/
v), 10% charcoal stripped FBS, 2 mmol/L glutamax-I, 0.25
µg/mL ascorbic acid, 0.5 mg% insulin (Sigma), 1 µg%
transferrin (Sigma), antibiotic and fungizone), similarly
to ESC. In both cell cultures, the media were changed
every 3 days. Upon reaching confluence, ESC and EEC
were passaged by treatment with 0.5 g/L tripsin-0.2 g/L
EDTA solution (GibcoBRL).
The purity of cell cultures was greater than 90% for ESC
and EEC, evaluated by immunocytochemistry of vimentin
and cytokeratin, respectively.
Epithelial and stromal cell culture
Cells, EEC and ESC, were grown in appropriate medium
in 6-well or 96-well plates at 2.5 × 105 cells/well or 0.1 ×
105 cells/well, respectively. When cells were subconfluent
(48 – 72 h of culture), the media were changed to Hank's
media and incubated for 24 h. Then, the cells were incu-
bated in fresh Hank's media at 37°C in 5% CO2/air in
humidified atmosphere in the absence or presence of
androstenedione 10-6 M or androstenedione 10-6 M plus
hydroxyflutamide 10-5 M. The latter was added 15 min
before androstenedione. The culture was carried out for
24 h to evaluate the early effect of androstenedione on cell
survival. The concentration of androstenedione used in
the present investigation was established in dose-response
experiments and are in agreement with those previously
reported [14].
Immunohistochemical detection
Sections (4 to 6 µm) of human endometrial tissue
obtained from cultured explants were deparaffinized in
xylene and hydrated gradually through graded alcohols.
Endogenous peroxidase activity was prevented by incu-
bating the samples in 3% hydrogen peroxide for 5 min.
The sections were incubated in 10 mM sodium citrate
buffer (pH 6.0) at 95°C for 20 min. Nonspecific antibody
binding was prevented with 2% PBS-BSA for 1 h. Primary
antibody of Ki-67 (1:200; Novocastra Laboratories, New-
castle, UK) was applied to the samples and incubated
overnight at 4°C; the antibody for caspase-3 (1: 100; R&D
System, Inc., Minneapolis, MN) was incubated for 1 h at
37°C and the antibody for androgen receptor (AR) was
incubated overnight at 4°C (1: 75; Santa Cruz, CA, USA).
The second antibody used in both cases was a biotinylated
rabbit antimouse immunoglobulin. The reaction was
developed by the streptavidin-peroxidase system and
3,3'diaminobenzidine was used as the chromogen; coun-
terstaining was carried out with hematoxylin. The slides
were evaluated in a Nikon optical microscope (Nikon
Inc., Melville, NY, USA). The immunohistochemical eval-
uation was determined as the percentage of positive
stained cells. In all cases, at least 500 cells were evaluated
by three independent observers.
In Situ 3'-End Labeling of DNA in Apoptotic cells (TUNEL)
Programmed cell death was detected using TdT-mediated
dUTP nick end labeling as previously described (Promega,
Madison, WI, USA) [18]. Briefly, paraffin sections were
dewaxed with xylene and rehydrated for 3'-end labeling.
Tissue sections were incubated with proteinase K (20 µg/
ml) at room temperature for 10 min and washed with PBS
for 5 min. Then, incubated for 1 h at 37°C with the nucle-
otide mix labelled with fluorescein and terminal deoxynu-
cleotidyl transferase enzyme and counterstained with
propidium iodide. The number of apoptotic cells was
quantified by at least counting 1000 cells in a fluorescence
microscope by three independent observers. The number
of apoptotic cells was expressed as the percentage of posi-
tive cells.
Cell proliferation
CellTiter 96 AQueous Cell Proliferation Assay (Promega)
was used to perform cell proliferation, following manu-
facturer's instructions. Briefly, EEC or ESC were plated in
96-well until sub-confluence; then, the cells were cultured
with androstendione 10-6 M alone or androstenedione 10-
6 M with hydroxyflutamide 10-5 M, as described above.
Twenty µL of a mix of tetrazolium compound (3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl) 2H-tetrazolium; MTS) and an electron
coupling reagent (phenazine methosulfate; PMS) were
added to each well and incubated for 2 h at 37°C. The
quantity of the soluble formazan product was measured at
450-nm absorbance in an ELISA reader (Sigma) and
expressed as optical density units (OD).
Detection of apoptosis by Annexin V
Apoptosis was performed using Annexin V-FITC Apopto-
sis Detection Kit (Oncogene Reasearch Products, Boston,
MA, USA). Briefly, after EEC and ESC achieved sub-con-
fluence in 6-well plates, the cells were incubated with
androstenedione 10-6 M alone or androstenedione 10-6 M
with hydroxyflutamide 10-5 M, as described above. TheReproductive Biology and Endocrinology 2004, 2:81 http://www.rbej.com/content/2/1/81
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cells were dissociated by 0.25 g/L trypsin-0.1 g/L EDTA
treatment, gently re-suspended in cold binding buffer to
approximately 1 × 106 cells, and incubated with Annexin
V-FITC, as indicated by the manufacturer. The cells were
counter-stained with propidium iodide, analyzed and
counted by two independent observers in at least 1000
cells in each experimental condition using a fluorescent
and optical microscope (Nikon, UFX-NX model. Nikon
Inc., Melville, NY, USA). The results are expressed as per-
centage of apoptotic Annexin V-FITC positive cells respect
to total cells counted.
RNA isolation and semiquantitative Reverse 
Transcription-Polymerase Chain Reaction
Total RNA was isolated using TRIzol Reagent (GibcoBRL)
from endometrial tissue and ESC culture according to the
manufacturer's instructions. Total RNA was then reverse
transcribed, and cDNA was subjected to polymerase chain
reaction (PCR) using specific primers for ERα and
ERβ[24], bcl-2 and bax cDNA (NIDig 4558699) [7,18]. β-
actin was used as an internal control.
Semiquantitative RT-PCRs were achieved in the exponen-
tial linear zone amplification for each gene studied. Two
µg of total RNA were used for reverse transcription in a
total volume of 20 µl using the Revertaid H Minus M-
Mulv Reverse (Fermentas Hannover, MD, USA). The PCR
condition for ERα and ERβ was 2 mM MgCl2, 0.15 mM of
dNTP, 0.63 U of Taq DNA polymerase (Fermentas Han-
nover, MD, USA), and 0.4 µM of each primer; for bcl-2
and bax was 3 mM MgCl2, 0.25 mM of dNTP, 0.63 U of
Taq DNA polymerase, and 0.4 µM of each primer. The
PCR amplification was carried out in the Thermocycler,
model PTC-100 (MJ Research Inc, Watertown, MA), as
previously reported [23].
The PCR products were electrophoretically resolved on
1% agarose gel and stained with ethidium bromide. The
bands were evaluated using an image analyser (Kodak
Electrophoresis Documentation and Analysis System
[EDAS 290] and Kodak 1D Image Analysis software,
Rochester, NY, USA), and normalized relative to β-actin
PCR product and expressed as arbitrary units (AU).
To confirm the specificity of RT-PCR products, the frag-
ments were purified with CONCERT Rapid PCR Purifica-
tion System (GibcoBRL) and sequenced using an ABI
PRISM310 automated Sequencer (Perkin Elmer; Norwalk,
CT, USA).
Statistical evaluation
The results are expressed as the percentage of changes
obtained in the treated respect to the basal condition.
Comparisons between groups were performed by ANOVA
following Dunnett test. The significance level was set at
5%. Results are expressed as mean ± standard error of the
mean (SEM).
Results
Explants culture
In all samples, the expression of the AR was present in the
nucleus of EEC and ESC cells (data not shown). Moreover,
in EEC showed a positive staining in the cytoplasm. The
nucleolar antigen Ki-67 was detected in the nucleus of
EEC and ESC. After six hours of incubation with andros-
tenedione at different concentrations (10-7 M – 10-5 M),
the percentage of positive cells increased significantly only
in the presence of androstenedione 10-6 M and on the
stromal compartment (basal: 9,9 ± 2.5%; treated: 21.2 ±
6.4%; p < 0.05) (Figures 1A and 1D). Therefore, the fol-
lowing experiments were performed at a concentration of
androstenedione 10-6 M.
On the other hand, TUNEL positive cells were lower in
ESC after androstenedione treatment (basal: 21.2 ± 5.0%;
treated:10.3 ± 3.7%; p < 0.05), (Figures 1B and 1E). The
expression of caspase-3 did not change with the andros-
tenedione treatment in both compartments (Figures 1C
and 1F). The addition of hydroxyflutamide plus andros-
tenedione did not modify the degree of proliferation or
cell death in tissue explants.
Isolated endometrial cells
Basal values of cell proliferation were 0.39 ± 0.09 OD and
0.64 ± 0.16 OD for EEC and ESC, respectively, whereas,
the percentage of annexin V positive cells was 16.3 ± 4.6%
for EEC and 12.7 ± 4.3% for ESC. The addition of andros-
tenedione significantly increased cell proliferation in ESC
cultures (Table 1; p < 0.05), and this effect was reverted by
the addition of hydroxyflutamide (0.63 ± 0.16 OD vs 0.70
± 0.19 OD); no changes were observed in the EEC sub-
population (Table 1).
The percentage of cells with positive signs of apoptosis
was similar between the basal and the treated conditions,
independently of the cell type analyzed. The addition of
hydroxyflutamide plus androstenedione to both cell cul-
tures did not modify the degree of cell death (Table 1).
Effect of androstenedione on the abundance of messenger 
RNA for bcl-2 and bax
A similar mRNA abundance for bcl-2 and bax was
obtained in tissue explants without treatment (bcl-2; 0.96
± 0.12 AU; bax: 0.99 ± 0.17 AU). Table 2 shows the effect
of androstenedione on the mRNA abundance of bcl-2 and
bax in endometrial explants. For bcl-2, the level of its
mRNA decreased with androstenedione treatment (p <
0.05) and hydroxyflutamide inhibited this effect,
whereas, the mRNA abundance of bax did not change
with the treatment. Despite these results, a similar bcl-2/Reproductive Biology and Endocrinology 2004, 2:81 http://www.rbej.com/content/2/1/81
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Effect of androstendione on endometrial cell proliferation and apoptosis of human endometria Figure 1
Effect of androstendione on endometrial cell proliferation and apoptosis of human endometria. Basal condition (left panel) and 
androstenedione-treated explants (right panel). The nucleolar antigen Ki-67, evaluated by immunohistochemistry, was 
detected in the nucleus of both cell compartments (A, D), indicative of cell proliferation. The nucleus of positive cells for 
TUNEL, determined by TdT-mediated dUTP nick end labeling, were stained in yellow and counterstained with propidium 
iodide (B, E), showing DNA fragmentation. The positive staining for caspase-3, determined by immunohistochemistry in paraf-
fin wax sections of endometria, was found in the cell cytoplasm of both compartments (C, G). Negative controls (inserts) for 
inmunohistochemistry was performed with non-immune rabbit serum in the place of the respective primary antibody and for 
TUNEL, by the replacement of TdT enzyme. Arrowheads indicate positive staining of the respective proteins. Magnification in 
all panels, ×400.Reproductive Biology and Endocrinology 2004, 2:81 http://www.rbej.com/content/2/1/81
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bax ratio was obtained (basal: 1.06 ± 0.21; treated: 0.99 ±
0.12).
In isolated cells, the basal mRNA abundance for bcl-2 in
EEC was 0.47 ± 0.07 AU and for bax 0.39 ± 0.25 AU and
in ESC, basal expression of bcl-2 mRNA was 0.87 ± 0.16
AU and 1.09 ± 0.10 AU for bax. Androstenedione induced
a decrease of 58% of bcl-2 mRNA expression (p < 0.05)
and a 30% increase of bax mRNA (p < 0.05) in EEC (Fig-
ure 2); therefore, the ratio bcl-2/bax was significantly
lower compared to the basal condition (p < 0.05). In ESC,
no significant differences on mRNA expression for bcl-2
and bax were found between the basal and androgen-
treated conditions. No important changes in mRNAs
expression were observed when hydroxyflutamide was
added to both cell culture systems.
Effect of androstenedione on messenger RNA abundance 
of steroid receptors
In the endometrial explant cultures, the abundance of
mRNA for ERα was similar between the basal condition
and the tissue treated with androstenedione (0.44 ± 0.12
AU; 0.41 ± 0.07 AU, respectively). In contrast,
androstenedione treatment induced a decrease in ERβ
mRNA abundance (basal: 0.91 ± 0.11 AU ; treated: 0.75 ±
0.08 AU; p < 0.05). However, the ratio between the level
of ER isoforms did not change. No significant modifica-
tions were observed when hydroxyflutamide was added to
the cultures.
On the other hand, basal expression of ERα mRNA was
0.31 ± 0.05 AU and 0.39 ± 0.08 AU for ERβ in EEC; in ESC
was 0.82 ± 0.23 AU for ERα and 0.86 ± 0.28 AU for ERβ.
Androstenedione tended to modify mRNA abundance of
ERα in EEC and ESC, a 30% and 25% diminution was
obtained, respectively (p = 0.07). In EEC, gene expression
of ERβ increased 48% with androstenedione (0.39 ± 0.08
AU vs 0.56 ± 0.18, p < 0.05) (Figure 3), with no modifica-
tion in ESC. Therefore, the ratio between the expression of
ER isoforms decreased 70% in EEC. Hydroxyflutamide
reverted the effect of androstenedione on gene expression
of ERβ and on the ratio ERα/ERβ.
Discussion
The present investigation represents an interesting
approach that associates the potential effect of androgens
on endometrial cell survival. By means of two in vitro
models, we could observe that androstenedione can mod-
ulate the proliferation and apoptosis of the stromal
compartment and modify the mRNA abundance of pro-
teins related to apoptosis and β-isoform of ER in EEC.
Table 1: Effect of androstenedione in cell proliferation and apoptotic index in endometrial epithelial cells (EEC) and endometrial 
stromal cells (ESC) in vitro.
Cell Proliferation (%) Apoptotic index (%)
E E CE S CE E CE S C
Basal 100 100 100 100
Androstenedione (10-6 M) 91.6 ±   6.9 135.4   ± 1.2* 165.0 ± 59.0 120.0   ± 11.0
Androstenedione (10-6 M) 
plus hydroxyflutamide (10-5 
M)
99.1  ±  10.0 109.2  ±  4.2 111.2  ±  6.3 106.7  ±  7.4
*p < 0.05. Values are calculated as percentage of basal and are expressed as mean ± SEM.
Table 2: Effect of androstenedione in the mRNA abundance for bcl-2 and bax in endometrial tissue explants.
bcl-2 (%) bax (%)
Basal 100 100
Androstenedione (10-6 M) 73.6 ± 3.9* 90.0 ± 20.9
Androstenedione (10-6 M) plus 
hydroxyflutamide (10-5 M)
86.7 ± 14.5 113.3 ± 37.1
*p < 0.05. Values are calculated as percentage of basal and are expressed as mean ± SEM.Reproductive Biology and Endocrinology 2004, 2:81 http://www.rbej.com/content/2/1/81
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Thereby, in explant cultures, androstenedione stimulated
cell proliferation in stroma. One possible explanation to
this finding may be related to the fact that androgens can
induce the expression of the receptor of epidermal growth
factor in the stromal compartment, as reported previously
[25]. In turn, the increase in the proliferation rate may
occur through an indirect effect of the growth factor on
stromal cells.
Also, in the tissue explants model we observed that
androstenedione induced a diminution in the apoptosis
degree; although, the abundance of bcl-2 gene decreased.
This observation may be in contrast to the mechanism
that regulates apoptosis in cells; however, the ratio bcl-2/
bax did not change and, concomitantly, we did not
observe important differences in the expression of cas-
pase-3. This is a relevant point because according to
previous reports the control of cell death is principally
associated with an unbalance in the expression of proteins
related to the bcl-2 family, mainly bcl-2 and bax [17,18].
These findings may suggest that alternative apoptotic
pathways can be also operating in the endometrial cells.
On the other hand, it is well known that in endometrial
tissue, estrogen actions mediated through their own
receptors have been related to cell survival and progres-
sion of proliferation. Furthermore, during the menstrual
cycle, it has been demonstrated the presence of the
Polymerase chain reaction (PCR) amplification from reverse-transcribed cDNA from endometrial epithelial cells (EEC) under  the stimulation with androstenedione 10-6 M, using primers for bcl-2, bax and β-actin Figure 2
Polymerase chain reaction (PCR) amplification from reverse-transcribed cDNA from endometrial epithelial cells (EEC) under 
the stimulation with androstenedione 10-6 M, using primers for bcl-2, bax and β-actin. Results represent six experiments per-
formed in duplicate. Normalized yield for bcl-2 and bax PCR fragments relative to β-actin. PCR products from different exper-
iments are shown as percentage respect to basal. The values are expressed as mean ± SEM. ap < 0.05 between basal vs 
androstenedione.Reproductive Biology and Endocrinology 2004, 2:81 http://www.rbej.com/content/2/1/81
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isoforms α and β of ER in endometrial tissue [26,27].
Moreover, it has been postulated that the expression of
ERα may be associated to bcl-2 gene expression [28].
Studies in other reproductive tissues have also suggested
that ERβ could be involved in the inhibition of cell prolif-
eration [29,30]. Therefore, it acquires great relevance the
relationship between α and β isoforms of ER, considering
that both isoforms could have an antagonistic action lig-
and-dependent, in accordance to the relative expression of
each isoform in different tissues [16,31]. In the tissue
explant model used in the present study, in contrast to a
previous report [8], we were unable to demonstrate an
increase of ERα. Nevertheless, we observed a decrease of
the β-isoform of ER under the effect of androstenedione,
which could be associated to the increase of stromal cell
proliferation detected in the explants. Numerous clinical
and in vitro studies have suggested that the imbalanced of
ERα/ERβ is a common feature and could be critical in the
progression of estrogen-dependent tumors. It seems that
ERβ is an important modulator of the mitogenic action
estrogen and it confers protection against the ERα hyper-
proliferation [32]. Moreover, in prostate carcinoma cells
the expression of ERβ has been associated with triggers of
apoptotic pathway, similar to observed in models of ovar-
ian cancer cells [33,34]. Therefore, the observations in our
models open an important field in a possible relationship
between androgens effects with control of ERβ-mediated
cell proliferation
Polymerase chain reaction (PCR) amplification from reverse-transcribed cDNA from endometrial epithelial cells (EEC) under  the stimulation with androstenedione 10-6 M, using primers for ERα, ERβ and β-actin Figure 3
Polymerase chain reaction (PCR) amplification from reverse-transcribed cDNA from endometrial epithelial cells (EEC) under 
the stimulation with androstenedione 10-6 M, using primers for ERα, ERβ and β-actin. Results represent six experiments per-
formed in duplicate. Normalized yield for ERα and ERβ PCR fragments relative to β-actin. PCR products from different exper-
iments are shown as percentage respect to basal. The values are expressed as mean ± SEM. a P < 0.05 between basal vs 
androstenedione.Reproductive Biology and Endocrinology 2004, 2:81 http://www.rbej.com/content/2/1/81
Page 9 of 10
(page number not for citation purposes)
When isolated cells were evaluated, some differences were
obtained in the parameters studied compared to the
explant cultures, which highlight the importance of the
relationship between the different cell compartments in
the regulation of the cell survival [35].
In ESC, androstenedione stimulated cell proliferation
with no changes in the apoptosis degree nor on the
expression of the genes bcl-2 and bax. This observation
suggests that ESC exhibit an independent capacity to
respond to androstenedione, whose action may be medi-
ated by the androgen receptor. The latter is based mainly
on the effect of the competitive inhibitor of the androgen
receptor, hydroxyflutamide, which reverts the effect of
androstenedione in the two models.
In EEC, androstenedione induced a diminution in the
ratio between the mRNA abundance of bcl-2 and bax
without an evident increase in the apoptosis degree. Pre-
vious studies in other models, such as breast cancer cell
lines, have demonstrated that androgens can induce a
decrease on the expression of bcl-2 and also an atrophy of
the mammary ephitelium [36]. The present observations
suggest that the mechanisms of control of cell death in
EEC are different from those of ESC, indicating that ESC
may be responsible in providing molecular and physical
interactions that can inhibit the early changes in the bal-
ance of apoptosis control genes in EEC.
In contrast to our results, a previous study showed that in
EEC cultures, androstenedione produces a fall in cell pro-
liferation [14]. In fact, we did not observe this phenome-
non, most likely due to technical differences in which the
treatment was performed for 24 h in the present study
with the aim to evaluate the early expression of genes
related to apoptosis.
Moreover, in EEC we observed that androstenedione up-
regulated the ERβ expression and hence, a decrease in
ER /ERβ ratio was obtained. The meaning of this effect
on cell survival is difficult to evaluate in our experimental
model, since no estradiol was added to the culture system.
Furthermore, it is unlikely that androstenedione may
produce estrogen by P450 aromatase activity, because nor-
mal endometrial cells present a very low expression of this
enzyme, as previously demonstrated [37]. However, in
EEC the decrease in ERα/ERβ may be related to an unbal-
ance of the bcl-2/bax ratio although this hypothesis needs
further studies.
Taking together our results, we can speculate that in the
presence of androgens the regulatory mechanisms of cell
survival in endometrial cells would be associated to the
interaction capacity elicited by the different cellular com-
ponents of the tissue. In fact, we postulate that androgens
induce an increase of proliferation in stroma, probably
related to growth factors and that these signals interact
with epithelial cells, promoting an inhibition on the
expression of genes related to cell death. In isolated cells,
the mechanisms that allow these interactions between cell
compartments are lost and the cells act according to their
proper feature.
Our findings on the effect of androstendione on cell pro-
liferation and apoptosis of ESC allows us to suggest a
potential regulatory action of androgen in the physiology
of the endometrium and its implications in the genesis of
endometrial pathologies frequently found in women with
hyperandrogenism. Even more, we have observed that
endometrial androstenedione concentration in women
with PCOS are three times higher than in normal women
during the proliferative phase [unpublished data). There-
fore, these in vitro models are important approaches to
understand the potential role of androstenedione in the
PCOS endometria. It is well established that women with
PCOS exhibit a high prevalence of hyperplasia and
endometrial cancer, which is associated with disturbances
in the regulation of cell survival [4-6]. According to our
results, androgens may be involved in these endometrial
alterations. However, we cannot ruled out the possible
action of hyperinsulinaemia, common feature observed
in PCOS women, which has been associated to increase
the potential for neoplastic change through theirs effects
on sex hormone binding-globulin (SHBG), insulin-like
growth factor-1 and estrogen concentrations [6,38].
Conclusions
In summary, our results indicate that androstenedione
may modulate cell survival, the expression of β-ER iso-
forms and proteins related to apoptosis. These observa-
tions are closely related to the control of endometrial cell
function and may help to understand the possible effect
of the hyperandrogemia on endometrial tissue.
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